FindTrial
Sign In

Translational study of prediction and treatment of hypertrophic cardiomyopathy based on genetics,image and clinics

Translational study of prediction and treatment of hypertrophic cardiomyopathy based on genetics,image and clinics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017627
Enrollment
Unknown
Registered
2018-08-07
Start date
2014-04-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertrophic cardiomyopathy

Interventions

hypertrophic cardiomyopathy cohort:Nil

Sponsors

The First Affiliated Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 93 Years

Inclusion criteria

Inclusion criteria: (1) =16 years of age; (2) Hypertrophic cardiomyopathy was defined as a maximum left ventricular wall thickness =15 mm unexplained by abnormal loading conditions or in accordance with published criteria for the diagnosis of disease in relatives of patients with unequivocal disease

Exclusion criteria

Exclusion criteria: (1) Left verntricular hypertrophic caused severe hypertension (Blood Pressur=160/100mmHg), metabolic disease, valvular heart disease, congenital heart disease,and so on; (2) Survivors from heart arrest; (3) Syncope or hemodynamic disorder caused by sustained ventricular tachycardia or ventricular fibrillation; (4) Missing follow-up data.

Design outcomes

Primary

MeasureTime frame
Clinical and image index;genetic technology assessment;Primary and secondaryt end points;—

Countries

China

Contacts

Public ContactLiwen Liu

The First Affiliated Hospital of Air Force Medical

liuliwen@fmmu.edu.cn+86 13571975528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026